CRBP vs. FULC, TBPH, PEPG, SLRN, LXRX, BMEA, TRDA, ANNX, ANL, and OCS Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Fulcrum Therapeutics (FULC), Theravance Biopharma (TBPH), PepGen (PEPG), Acelyrin (SLRN), Lexicon Pharmaceuticals (LXRX), Biomea Fusion (BMEA), Entrada Therapeutics (TRDA), Annexon (ANNX), Adlai Nortye (ANL), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Fulcrum Therapeutics (NASDAQ:FULC ) and Corbus Pharmaceuticals (NASDAQ:CRBP ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
In the previous week, Fulcrum Therapeutics had 31 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 36 mentions for Fulcrum Therapeutics and 5 mentions for Corbus Pharmaceuticals. Fulcrum Therapeutics' average media sentiment score of 0.27 beat Corbus Pharmaceuticals' score of 0.24 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
Corbus Pharmaceuticals received 336 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 66.51% of users gave Corbus Pharmaceuticals an outperform vote while only 64.63% of users gave Fulcrum Therapeutics an outperform vote.
Fulcrum Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.
Corbus Pharmaceuticals has lower revenue, but higher earnings than Fulcrum Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Corbus Pharmaceuticals' net margin of -3,470.05%. Corbus Pharmaceuticals' return on equity of -40.60% beat Fulcrum Therapeutics' return on equity.
Fulcrum Therapeutics presently has a consensus price target of $14.33, indicating a potential upside of 89.85%. Corbus Pharmaceuticals has a consensus price target of $61.00, indicating a potential upside of 35.56%. Given Corbus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Fulcrum Therapeutics is more favorable than Corbus Pharmaceuticals.
Summary Fulcrum Therapeutics beats Corbus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
